FDA approves Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared ...

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a ...

The husband of a Colorado woman whose remains were found after more than three years of searching has been rearrested on ...